111 filings
8-K
GNCAQ
Genocea Biosciences, Inc.
1 Jun 22
Departure of Directors or Certain Officers
4:09pm
8-K
GNCAQ
Genocea Biosciences, Inc.
24 May 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:10am
8-K
GNCAQ
Genocea Biosciences, Inc.
28 Apr 22
Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives
4:18pm
8-K
GNCAQ
Genocea Biosciences, Inc.
10 Mar 22
Genocea Provides Fourth Quarter 2021 Corporate Update
8:01am
8-K
GNCAQ
Genocea Biosciences, Inc.
7 Mar 22
John Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of Directors
4:19pm
8-K
n51kndgfa8e
4 Jan 22
Genocea Biosciences Provides Corporate Update
7:03am
8-K
tbi4 pbo7
28 Oct 21
Genocea Provides Third Quarter 2021 Corporate Update
7:42am
8-K
wptix4
13 Sep 21
Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors
4:55pm
8-K
b1kwltqitgk4
29 Jul 21
Genocea Provides Second Quarter 2021 Corporate Update
8:24am
8-K
x50oif 672v
13 Jul 21
Regulation FD Disclosure
8:46am
8-K
jye714zci3
24 Jun 21
Amendments to Articles of Incorporation or Bylaws
4:06pm
8-K
n9bcjxi197g
4 Jun 21
Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021
4:04pm
8-K
fnos14u6helfkx65i
29 Apr 21
Genocea Provides First Quarter 2021 Corporate Update
7:13am
8-K
hhzxvox1z7
14 Apr 21
Departure of Directors or Certain Officers
4:03pm
8-K
qlqrz
11 Feb 21
Genocea Provides Fourth Quarter 2020 Corporate Update
7:31am
8-K
5gfdt46yp
4 Jan 21
Regulation FD Disclosure
4:44pm
8-K
7esz826p7v
18 Nov 20
Regulation FD Disclosure
7:56am
8-K
11z1ym7rb 7y8
9 Nov 20
Regulation FD Disclosure
5:20pm
8-K
hp6a4o0d fahsd
9 Nov 20
Genocea Presents Positive GEN-009 Clinical Results, Update on GEN-011 Program and New InhibigenTM Mechanism of Action Data at Virtual SITC 2020
8:05am
8-K
kn08scqz 1nq
29 Oct 20
Genocea Provides Third Quarter 2020 Corporate Update
7:04am